Introduction
Magnetic resonance imaging (MRI) is a powerful technique for noninvasive diagnosis of the human anatomy, physiology, and pathophysiology on the basis of superior spatial resolution and contrast useful in providing anatomical and functional images of the human body.
1 At the clinical level, MRI techniques are mostly performed employing Gd-chelates to enhance the image contrast by increasing the water proton relaxation rate in the body. 2 Despite their wide and successful applications in clinics, however, conventional Gd-based low-molecular weight contrast agents are mostly ECF agents exhibiting rapid extravasation from the vascular space. As a result, the time window for imaging is considerably reduced, thus limiting acquisition of high-resolution images.
To overcome such limitations inherent to ECF MRI CAs, there has risen the necessity for the development of new MRI CAs carrying some unique functionalities. As a representative example, one may cite the so-called 'targeting MRI CAs' capable of responding to particular pathologies (i.e., tumors, angiogenesis, apoptosis). [3] [4] [5] [6] It would be even more desirable to equip the targeting imaging probes with such an additional function as therapy within a single molecule, from which a new term 'theranostic' (a coinage of diagnostic and therapeutic) may be derived.
We have recently reported the synthesis of DO3A-(paniline benzothiazole) conjugate (L Benzothiazole derivatives exhibit diverse biological properties such as anti-inflammatory, antimicrobial, and anticancer effects. As such, a great deal of research activities has been carried out in the past two decades in an effort to develop various benzothiazole derivatives with high antitumor activity.
8 Their antitumor properties have been utilized in combination with molecular imaging and therapy. For Re) have been proposed as potential radiopharmaceuticals for single photon emission computed tomography (SPECT) and radioimmunotherapy (RIT).
9,10 Benzothaizoles labeled with radioisotopes such as 99m Tc and
11
C have been proposed as potential probes for Ab-amyloid plaques in the brain.
11,12
More recently, DO3A conjugates of benzothiazoles have been employed as multimodal imaging probes such as magnetic resonance imaging (MRI)/optical and MRI/SPECT.
13,14
Motivated by such intriguing properties of benzothiazoles and by our recent observations cited above in connection with GdL 1 , we have decided to pursue further studies on the structure activity relationship for the theranostic application of benzothiazole derivatives. Here we wish to report the synthesis and evaluation of L 2 H 3 and GdL 2 as a potential theranostic agent.
Experimental
General. All reactions were performed under an atmosphere of dinitrogen using the standard Schlenk technique. Solvents were purified and dried using standard procedures. DO3A( t Bu) 3 (= 1,4,7,10-tetraazacyclododecane-1,4,7-tristert-butyl acetate) was prepared according to the literature method.
15 All other reagents were purchased from commercial sources and used as received unless otherwise stated. Deionized water was used throughout all experiments. The 1 H NMR experiments were performed on a Bruker Advance 400 Spectrometer by Center for Instrumental Analysis, Kyungpook National University (KNU). Chemical shifts were given as δ values with reference to tetramethylsilane (TMS) as an internal standard. Coupling constants are in Hz. FABmass spectra were obtained by using a JMS-700 model (Jeol, Japan) mass spectrophotometer by Korea Basic Science Institute (KBSI). Elemental analyses were conducted by using a Fisons EA 1108 model at Center for Instrumental Analysis, KNU.
Synthesis of 1,4,7,10-Tetraazacyclododecane-1,4,7-tristert-butyl acetate-10-[(6-bromomethylpyridyl)-2-methyl] (1). To a solution of 2,6-bis(bromomethyl)pyridine (1.0 g, 3.9 mmol) and K 2 CO 3 (1.2 g, 8.6 mmol) in CH 3 CN (50 mL) was added drop wise a solution of DO3A( (2) . To a mixture of 1 (1.0 g, 3.9 mmol) and K 2 CO 3 (1.0 g, 1.9 mmol) in acetone (50 mL) was added drop wise a solution of 2-(p-aniline)benzothiazole (0.8 g, 3.4 mmol) in acetone (100 mL). On completion of addition, the reaction mixture was stirred for 18 h at 45 o C, after which any solids were removed by filtration. The filtrate was evaporated under a reduced pressure. The crude compound was purified by chromatography (CH 2 Cl 2 /MeOH, 98:2) to give a paled yellow solid. Yield: 1.4 g (58%). . Deprotection of the tert-butyl groups from 2 was performed as follows: The compound 2 (0.8 g, 1.9 mmol) was added to a solution of TFA/CH 2 Cl 2 (1:3, 20 mL), and the mixture stirred at RT for 24 h. The solvents were removed by evaporation, the crude product dissolved in MeOH (5 mL), and diethyl ether (100 mL) added to precipitate an off-white solid. Yield: 0.6 g (96%). ® with zinc acetate, has given results identical to those obtained in the presence of ZnCl 2 . The R 1 P relaxation rate was obtained after subtraction of the diamagnetic contribution of the proton water relaxation from the observed relaxation rate R 1 = (1/T 1 ). The measurements were performed on a 3 T whole body system (Magnetom Tim Trio, siemens, Germany) at room temperature.
Relaxivity. T 1 measurements were carried out using an inversion recovery method with a variable inversion time (TI) at 1.5 T (64 MHz). The magnetic resonance (MR) images were acquired at 35 different TI values ranging from 50 to 1750 msec. T 1 relaxation times were obtained from the non-linear least square fit of the signal intensity measured at each TI value. For T 2 measurements the CPMG (CarrPurcell-Meiboon-Gill) pulse sequence was adapted for multiple spin-echo measurements. Thirty four images were acquired with 34 different echo time (TE) values ranging from 10 to 1900 msec. T 2 relaxation times were obtained from the non-linear least squares fit of the mean pixel values for the multiple spin-echo measurements at each echo time. Relaxivities (R 1 and R 2 ) were then calculated as an inverse of relaxation time per mM. The determined relaxation times (T 1 and T 2 ) and relaxivities (R 1 and R 2 ) are finally imageprocessed to give the relaxation time map and relaxivity map respectively.
In vivo MR Imaging and Image Analysis. All animal experiments were performed in accordance with the rules of the animal research committee of Kyungpook National University. Six-week male. (Iinstiture of Cancer Resarch) ICR mice with weights of 29-31 g were for the MRI. The mice were anesthetized by 1.5% isoflurane in oxygen. Measurements were made before and after injection of GdL After each measurement, the mouse was revived from anesthesia, and placed in the cage with free access to food and water. During these measurements, the animals were maintained at approximately 37°C using a warm water blanket. MR images were taken with an 1.5 Tesla (T) MR unit (GE Healthcare, Milwaukee, WI, USA) equipped with a home-made small animal RF coil. The coil was of the receiver type with its inner diameter being 50 mm. The imaging parameters for SE (Spin Echo) are as follows: repetition time (TR) = 300 ms; echo time (TE) = 13 ms; 7 mm field of view (FOV); 192 × 128 matrix size; 1.2 mm slice thickness; number of acquisition (NEX) = 8. Images were obtained for 300 min after injection. The anatomical locations with enhanced contrast were identified with respect to heart, kidney and liver on post-contrast MR images. For quantitative measurement, signal intensities in specific regions of interest (ROI) measured using Advantage Window software (GE Medical, USA). The CNR (Contrast to Noise Ratio) was calculated using Eq. (1), where SNR is the signal to noise ratio.
Results and Discussion Synthesis. Scheme 1 shows the preparative method leading to the formation of a new bifunctional chelate (BFC) L by simple complexation with an equimolar amount of gadolinium chloride in water. The complex was isolated as an off-white, hygroscopic solid by repeated precipitation with diethyl ether from the reaction mixture. All new compounds were characterized by microanalysis and various spectroscopic techniques such as 1 H NMR and HR-FAB mass spectroscopy.
Kinetic Inertness. The kinetic inertness of GdL 2 is represented by the evolution of the normalized paramagnetic longitudinal relaxation rates, R 1 P (t)/R 1 P (0) as a function of time (Figure 1) . Here, the relative value of R 1 P at any time t is a good estimator of the extent of transmetallation of gadolinium by zinc: GdL + Zn
. Of various endogenous ions, Zn(II) has been noted to displace more gadolinium ions due to its higher concentration in the blood than any other ions such as Cu(II), Ca(II), K(I).
16 Quite expectedly, GdL 2 exhibits high kinetic stability comparable with those of Gadovist ® and Dotarem ® employing the same type of macrocyclic chelate DO3A and DOTA (= 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakisacetic acid), respectively. Virtually no significant change in R 1 relaxivity is observed either with DO3A or DOTA for as long as 3 days. In contrast, however, other MRI CAs such as Multihance In vivo MRI. In vivo coronal images of mice obtained by tail vein injection with GdL 2 reveal strong signal enhancement in liver, heart, and abdominal aorta (Figure 3) . Gallbladder is also enhanced 40 minutes after injection indicating excretion is partially made through bile via hepatocyte in addition to the ordinary renal excretion. The contrast-to-noise ratio (CNR) curve provides a supporting evidence for the bile excretion (Figure 4) .
Tumor Targeting. GdL 2 shows a strong affinity toward the MDA-MB-231 tumor cell as observed from the in vivo CNR profiles along with MR images ( Figure 5 ). The maximum intensity endures for as long as 2 h in contrast to Dotarem ® , most of which excretes out of the body within 2 h.
Judging from our previous observations that GdL 1 possesses antiproliferative properties against a series of tumors, structurally related GdL 2 is considered to reveal similar behaviors as a single molecule theranostic agent. In this regard, it is to be highly recommended to pursue further a study on the structure-activity relationship (SAR) with GdL 2 , which is the subject of our future communication.
Conclusions
In conclusion, we have prepared DO3A conjugate of pyridylbenzothaizole (L 
